Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective, Controlled, Randomised, Cross-over Study Investigating the Pharmacokinetic Properties, Surrogate Efficacy and Safety of Octafibrin Compared to Haemocomplettan.Riastap in Subjects With Congenital Fibrinogen Deficiency

Next Previous
Trial Profile

A Prospective, Controlled, Randomised, Cross-over Study Investigating the Pharmacokinetic Properties, Surrogate Efficacy and Safety of Octafibrin Compared to Haemocomplettan.Riastap in Subjects With Congenital Fibrinogen Deficiency

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 20 Jan 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fibrinogen (Primary)
  • Indications Afibrinogenaemia
  • Focus Pharmacokinetics; Therapeutic Use
  • Sponsors Octapharma

Most Recent Events

  • 04 Dec 2018 Results assessing the efficacy and PK of Fibryga in Treating Acute Bleeding in Adolescent Patients with Congenital Fibrinogen Deficiency using data from FORMA-01 and FORMA-02 studies, presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
  • 08 Dec 2017 Primary endpoint of fibrinogen activity normalized area under the curve standardized (AUCnorm) has not been met according to results published in the Journal of Thrombosis and Haemostasis.
  • 08 Dec 2017 Primary endpoint of maximum clot firmness at 1 hr Post Infusion has not been met, according to results published in the Journal of Thrombosis and Haemostasis.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top